Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; I-131-Apamistamab (Primary) ; Antineoplastics
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SIERRA; SIERRA in AML
  • Sponsors Actinium Pharmaceuticals
  • Most Recent Events

    • 28 Oct 2019 Interim results from the study at 50% of total patient enrollment (n=75), presented in an Actinium Pharmaceuticals media release.
    • 24 Oct 2019 According to an Actinium Pharmaceuticals media release, the company will host a conference call and webcast to highlight interim results from this pivotal trial (findings from the first 50 percent of patients) for its lead program, Iomab-B.Management will be accompanied by Sergio Giralt, M.D., Chief Attending Physician, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center to present data.The conference call and webcast is scheduled to start on Monday on 28th Oct 2019.
    • 23 Jul 2019 According to an Actinium Pharmaceuticals media release, the 75th patient has been treated, thus achieving 50 percent patient enrollment for the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top